<DOC>
	<DOCNO>NCT02277587</DOCNO>
	<brief_summary>This randomize , control , open , three-armed , multi-centre study design compare effect dual-release hydrocortisone preparation versus conventional glucocorticoid therapy anthropometric parameter , metabolic syndrome , infectious , immunological profile , cardiovascular system , bone mass quality life patient affect primary secondary adrenal insufficiency .</brief_summary>
	<brief_title>Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy Hypocortisolism ( DREAM )</brief_title>
	<detailed_description>Hypocortisolism disease 80 % 1-year mortality availability synthetic glucocorticoid . Current replacement therapy improve dramatically , recent data suggest outcome still compromise . Patient receive conventional glucocorticoid therapy compromise quality life , reduce bone mass , increase risk factor cardiovascular disease , infectious , tumor premature mortality twice mortality rate background population . Circulating cortisol level follow distinct diurnal pattern high level early morning low trough value around midnight . Using available formulation replacement therapy circadian rhythm mimic also active time day high peak low trough occur . In trial dual-release hydrocortisone preparation healthy volunteer able mimic circadian pattern circulate cortisol study patient primary secondary adrenal insufficiency .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<mesh_term>Addison Disease</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<criteria>Previously diagnose ( e.g . 6 month ago ) primary secondary adrenal insufficiency stable daily glucocorticoid substitution dose least 3 month prior study entry Signed informed consent participate study acute primary secondary adrenal insufficiency clinical laboratory sign significant cerebral , cardiovascular , respiratory , hepatobiliary , pancreatic disease clinically significant renal dysfunction medication agent could interfere glucocorticoid kinetics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Plenadren</keyword>
	<keyword>Addison 's disease</keyword>
	<keyword>Hydrocortisone</keyword>
	<keyword>Cortisone Acetate</keyword>
	<keyword>Monocytes</keyword>
	<keyword>Natural Killer cell</keyword>
	<keyword>Immunological profile</keyword>
	<keyword>Inflammation</keyword>
</DOC>